Article Date: 14 Aug 2013 - 0:00 PDT
Current ratings for:
Drugs that clog 'waste disposal' may treat aggressive breast cancers
In a new paper in Cancer Cell, a team led by Judy Lieberman, PhD, of Boston Children's Hospital's Program in Cellular and Molecular Medicine reports "triple-negative" breast cancers may be vulnerable to drugs that attack the proteasome. This cellular structure acts as the cell's waste disposal, breaking down damaged or unneeded proteins.
These cancers, which lack the three major therapeutic markers for breast cancer - the estrogen, progesterone and HER2 receptors - are very aggressive and difficult to treat. They mostly affect younger women and have the worst prognosis of all breast cancers.
By selectively turning genes off throughout the genomes of triple-negative tumor cells in vitro, Lieberman's team found that these cells absolutely require active proteasomes in order to live. When turned off, the cells die.
These data suggest that triple-negative breast cancers may respond to treatment with drugs similar to bortezomib (Velcade®), a proteasome inhibitor that revolutionized the care of patients with the blood cancer multiple myeloma.
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.Visit our breast cancer section for the latest news on this subject.
The study was supported by the Department of Defense Breast Cancer Research Program, the National Cancer Institute (grant number R01CA146445) and the Breast Cancer Research Foundation.
A Genome-wide siRNA Screen Identifies Proteasome Addiction as a Vulnerability of Basal-like Triple-Negative Breast Cancer Cells
Cancer Cell, Volume 24, Issue 2, 182-196, 12 August 2013. 10.1016/j.ccr.2013.07.008
Boston Children's Hospital
Please use one of the following formats to cite this article in your essay, paper or report:MLA
14 Aug. 2013.
Please note: If no author information is provided, the source is cited instead.
'Drugs that clog 'waste disposal' may treat aggressive breast cancers'
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
No comments:
Post a Comment